Precigen (PGEN) Could Be 50% Undervalued On Strong Earnings Turnaround

Why Precigen’s latest earnings drew investor attention

Precigen (PGEN) has drawn fresh interest after its 4 August 2026 earnings release, which showed second quarter revenue of US$54.98 million and net income of US$20.07 million, compared with losses in the prior year period.

See our latest analysis for Precigen.

Since those results on 4 August 2026, Precigen’s recent earnings swing to profit has coincided with strong momentum, with a 30 day share price return of 35.9% and a 1 year total shareholder return above 300%.

If you are weighing Precigen’s move and want fresh ideas in a similar area, it could be worth scanning other healthcare focused AI opportunities through the 43 healthcare AI stocks

After a 1 year return above 300% and a share price near US$7.23 against analyst targets around US$14.50, Precigen now trades at a steep implied discount. Is this market caution still warranted given its latest earnings shift?

Most Popular Narrative: 50.1% Undervalued

Precigen’s most followed narrative points to a fair value of $14.50 against the recent $7.23 close, which puts the current rally in a very different light.

Rapid uptake of PAPZIMEOS in a sizable and previously underserved adult RRP population, combined with strong physician enthusiasm and broad label coverage, supports a multi year ramp in product revenue as pent up demand converts into treated patients.

Read the complete narrative.

Want to see what sits behind that optimism on PAPZIMEOS uptake? The narrative focuses on aggressive revenue scaling, sharply higher margins and a richer future earnings multiple. The full set of assumptions is where the real story shows up.

Result: Fair Value of $14.50 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Precigen’s story still hinges heavily on PAPZIMEOS, so any setback in real world outcomes or slower than expected uptake could quickly challenge this undervalued narrative.

Find out about the key risks to this Precigen narrative.

Another view on Precigen’s valuation

The analyst narrative points to Precigen trading well below a US$14.50 fair value, yet current market ratios tell a different story. At a P/S of 30.2x against a fair ratio of 10.3x, and 11.4x for the US Biotechs industry and 9.5x for peers, the stock looks richly priced. Could the market already be baking in a lot of that bullish PAPZIMEOS scenario?

For a closer look at how these ratios fit together with the assumptions behind them, take a moment to review the valuation breakdown in the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With Precigen’s story pulling in both optimism and caution, this is a moment to move quickly and test the assumptions yourself through the 1 key reward and 3 important warning signs

Looking for more Precigen style investment ideas?

If Precigen has sharpened your focus on what is possible, do not stop here. Use the Simply Wall Street Screener to spot other stocks that match your criteria before the crowd moves on.

• Target potential turnaround opportunities early by scanning 20 elite penny stocks with strong financials, which pair smaller size with stronger underlying numbers than many expect.
• Zero in on companies that combine quality with pricing appeal using the 52 high quality undervalued stocks to see where fundamentals and market expectations differ.
• Prioritise resilience by checking out the 83 resilient stocks with low risk scores and focus on stocks that score well on financial strength and risk factors.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com